What is the primary purpose of using low molecular weight heparins in critically ill patients?

The primary purpose of using low molecular weight heparins (LMWH) in critically ill patients is to prevent deep vein thrombosis (DVT). Critically ill patients are at a high risk for thromboembolic events due to factors such as immobility, dehydration, and the inflammatory response associated with their illness. LMWH works by inhibiting factor Xa and thrombin in the coagulation cascade, leading to an anticoagulant effect that reduces the likelihood of clot formation in the veins.

This preventative measure is crucial in a critical care setting, where DVT can lead to serious complications like pulmonary embolism if not managed effectively. While factors like blood pressure management, wound healing, and treating infections are essential components of patient care, they are not the primary indication for using LMWH in this context. The main aim remains focused on the reduction of thrombotic risks for those immobilized or critically ill.